HADLIMA (adalimumab-bwwd) injection recall
FDA recall D-0099-2026 · initiated Oct 10, 2025
Samsung Bioepis Co., Ltd. recalled HADLIMA (adalimumab-bwwd) injection in Oct 2025 — an FDA Class II recall (D-0099-2026) because Lack of Assurance of Sterility.
May cause temporary or medically reversible harm; low probability of serious harm.
Why it was recalled
Lack of Assurance of Sterility.
Sterility could not be assured
The maker could not guarantee the product was sterile. That matters most for injections and eye products, where a contaminated dose reaches past the body's defences.
This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.
Is your product affected? Check the lot number
A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.
Quantity recalled: 5,518 packs (11,036 Syringes) 2 syringes/carton)
Details
- Product
- HADLIMA (adalimumab-bwwd) injection, 40mg/0.8 mL, 2 Single-dose Prefilled Syringes per carton, Rx only, Manufactured for: Organon LLC, a subsidiary of ORGANON & Co, Jersey City, NJ 07302, Manufactured by: SAMSUN BIOEPIS Co., Ltd, Incheon, Republic of Korea, NDC 78206-183-01.
- Recalling company
- Samsung Bioepis Co Ltd
- Classification
- Class II
- Status
- Ongoing
- Type
- Voluntary: Firm initiated
- Distribution
- Distributed only to one warehouse in NJ. with no further distribution
- Initiated
- Oct 10, 2025
- FDA report date
- Nov 5, 2025
Frequently asked
- Was HADLIMA (adalimumab-bwwd) injection recalled?
- Samsung Bioepis Co., Ltd. recalled HADLIMA (adalimumab-bwwd) injection in Oct 2025 — an FDA Class II recall (D-0099-2026) because Lack of Assurance of Sterility. May cause temporary or medically reversible harm; low probability of serious harm.
- Why was HADLIMA (adalimumab-bwwd) injection recalled?
- Per the FDA enforcement record, the reason for recall D-0099-2026 was: Lack of Assurance of Sterility.
- Is a recalled HADLIMA (adalimumab-bwwd) injection dangerous to take?
- An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
- Which lots of HADLIMA (adalimumab-bwwd) injection are affected?
- Distributed: Distributed only to one warehouse in NJ. with no further distribution. The recall covers these lots — Lot: F2505017, Expiry: 24-Jan-2027. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0099-2026.